Lung cancer occurs when cells in the lung grow abnormally out of control and form tumors
Lung cancer includes two main types
- Non-small cell lung cancer (NSCLC)
- Small cell lung cancer
80% - 85% of lung cancers are NSCLC
Used to treat NSCLC by preventing the activity of EGFR, a protein involved in the growth and spread of cancer cells.
- EGFR positive metastatic NSCLC
- Metastatic pancreatic cancer
Before Taking Erlotinib
All About Your Medical Conditions, Including
Not recommended in severe liver disease
Not recommended in severe kidney disease
If you have an intolerance to some sugars, such as lactose.
It is advised to stop smoking if you are treated with Erlotinib
Erlotinib is not recommended for children and adolescents.
Do not breast-feed if you are being treated with Erlotinib, and for at least 2 weeks after taking the last tablet.
Do not take Erlotinib with food
During Erlotinib Therapy
Inform Your Doctor If You Experience
- Sudden difficulty in breathing with cough
- Persistent diarrhea and loss of appetite
- Nausea or Vomiting
- Severe pain in the abdomen
- Redness and pain in the eye
- Severe blistering or peeling of skin
Always take erlotinib exactly as directed by your doctor
At least 1 hour before or 2 hours after food.
The usual dose is:
- For NSCLC
1 Tablet - 150 mg OD
- For Pancreatic Cancer
1 Tablet- 100 mg OD
- If you take more Erlotinib than needed, contact your doctor immediately.
- If you miss one or more doses contact your doctor as soon as possible.
- Do not take a double dose to make up for a missed dose.
- Its important to take daily dose as prescribe by the Doctor
Like all medicines, this can also cause some side effects in few people. Contact your doctor as soon as possible if you have any of the below side effects.
- Rash which worsens in sun exposed areas
- Altered skin sensation or numbness
- Decreased weight
- Loss of appetite
- Depression and Headache
- Severe or persistent diarrheoa
- Difficulty in breathing
- Mouth irritation
- Stomach pain indigestion and flatulence
- Itching and dry skin
- Loss of hair
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date written on the blister and carton.
To report any side-effects, write to firstname.lastname@example.org . You can also report side effects directly via the national pharmacovigilance program of India by calling on 1800 180 3024 or you can report to Cipla Ltd on 1800 267 7779. By reporting side-effects, you can help provide more information on the safety of this product.
NSCLC: Non -Small Cell Lung Cancer; EGFR: Epidermal growth factor receptor;
OD: Once daily.
1. Non-Small Cell Lung Cancer Treatment. httpps://www.cancer.gov/types/ lung/hp/non-small-cell-lung-treatment-pdq. last accessed 24th Mar 2021
2. What is lung cancer? https://www.cancer.org/cancer/lung-cancer/about/ what-is.html last accessed 24th Mar 2021.
3. Approved prescribing information of Erlotinib.